Immunosuppressive treatment in refractory chronic inflammatory demyelinating polyradiculoneuropathy

Author(s): Cocito D, Grimaldi S, Paolasso I, Falcone Y, Antonini G, et al.

Abstract

Background and purpose:There are other options open to patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) who are non-responders to conventional treatment, including immunosuppressive and immunomodulatory agents (IA). The aim of this study was to assess whether the use of IA is able to increase the number of responders.

Methods:Clinical and electrophysiological data of patients with refractory CIDP, followed at 10 Italian centres, were collected, and the clinical outcome (Rankin Scale) and drug side effects (SE) for the different therapies were analysed.

Results:A total of 110 patients were included. These patients underwent 158 different therapeutic procedures with IA. Seventy-seven patients were treated with azathioprine, 18 rituximab, 13 cyclophosphamide, 12 mycophenolate mofetil, 12 cyclosporine, 12 methotrexate, 11 interferon-alpha and three interferon beta-1a. The percentage of patients who responded to azathioprine (27%) was comparable to the percentage of responders to other therapies, after the exclusion of interferon beta-1a that was not effective in any of the three patients treated. The percentage of SE ranges from 8% (methotrexate) to 50% (cyclosporine).

Conclusions:One-fourth of patients, refractory to conventional treatment, showed an improvement in their disability with IA. Methotrexate had the lowest SE; cyclosporine was associated with severe SE and often led to drug discontinuation.

Similar Articles

Safety of intravenous immunoglobulin (IVIG) therapy

Author(s): Katz U, Achiron A, Sherer Y, Shoenfeld Y

Intravenous immunoglobulin: adverse effects and safe administration

Author(s): Orbach H, Katz U, Sherer Y, Shoenfeld Y

Complications of intravenous immune globulin treatment in neurologic disease

Author(s): Brannagan TH 3rd, Nagle KJ, Lange DJ, Rowland LP

Adverse effect of polyvalent immunoglobulin in the treatment of Guillain-Barre syndrome

Author(s): Chamouni P, Tamion F, Gueit I, Girault C, Lenain P, et al.

Patient demographics and health plan paid costs in chronic inflammatory demyelinating polyneuropathy

Author(s): Guptill JT, Bromberg MB, Zhu L, Sharma BK, Thompson AR, et al.

Diffuse muscular coactivation [DMC] as a potential source of pain in fibromyalgia -- part 1

Author(s): Donaldson CC, Snelling LS, MacInnis AL, Sella GE, Mueller HH

Pregabalin for fibromyalgia: some relief but no cure

Author(s): Kim L, Lipton S, Deodhar A

The effects of pregabalin on sleep disturbance symptoms among individuals with fibromyalgia syndrome

Author(s): Russell IJ, Crofford LJ, Leon T, Cappelleri JC, Bushmakin AG, et al.

The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia

Author(s): Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, et al.

Prevalence and factors associated with fibromyalgia in Mexican patients with systemic lupus erythematosus

Author(s): Valencia-Flores M, Cardiel MH, Santiago V, Resendiz M, Castaño VA, et al.

The prevalence and characteristics of fibromyalgia in the general population

Author(s): Wolfe F, Ross K, Anderson J, Russell IJ, Hebert L

Estimates of the prevalence of arthritis and other rheumatic conditions in the United States

Author(s): Lawrence RC, Felson DT, Helmick CG, Arnold LM, Choi H, et al.

Prevalence of fibromyalgia in children: a clinical study of Mexican children

Author(s): Clark P, Burgos-Vargas R, Medina-Palma C, Lavielle P, Marina FF

Management of fibromyalgia syndrome

Author(s): Goldenberg DL, Burckhardt C, Crofford L

Fibromyalgia syndrome module at OMERACT 9: domain construct

Author(s): Mease P, Arnold LM, Choy EH, Clauw DJ, Crofford LJ, et al.

Toward development of a fibromyalgia responder index and disease activity score: OMERACT module update

Author(s): Mease PJ, Clauw DJ, Christensen R, Crofford LJ, Gendreau RM, et al.

Nerve ultrasound score in distinguishing chronic from acute inflammatory demyelinating polyneuropathy

Author(s): Kerasnoudis A, Pitarokoili K, Behrendt V, Gold R, Yoon MS

Clinical spectrum of chronic acquired demyelinating polyneuropathies

Author(s): Saperstein DS, Katz JS, Amato AA, Barohn RJ

Chronic inflammatory demyelinating polyradiculoneuropathy

Author(s): Barohn RJ, Kissel JT, Warmolts JR, Mendell JR

Chronic inflammatory polyradiculoneuropathy

Author(s): Dyck PJ, Lais AC, Ohta M, Bastron JA, Okazaki H, et al.

Derivation and validation of diagnostic criteria for chronic inflammatory demyelinating polyneuropathy

Author(s): Koski CL, Baumgarten M, Magder LS, Barohn RJ, Goldstein J, et al.

IVIG regulates BAFF expression in patients with chronic inflammatory demyelinating polyneuropathy (CIDP)

Author(s): Ritter C, Förster D, Albrecht P, Hartung HP, Kieseier BC, et al.

High prevalence of restless legs syndrome among patients with fibromyalgia: a controlled cross-sectional study

Author(s): Viola-Saltzman M, Watson NF, Bogart A, Goldberg J, Buchwald D